Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas

This phase II trial studies how well de-escalating the drugs dabrafenib and trametinib works in treating patients with low-grade gliomas that have a BRAF V600 gene mutation. Dabrafenib and trametinib are in a class of medications called kinase inhibitors. They work by blocking the action of abnormal proteins that signals tumor cells to multiply. This helps stop the spread of tumor cells. This trial may help doctors determine the best dosing strategy for patients who have received dabrafenib and trametinib for 12-24 months: Either stopping dabrafenib and trametinib completely or slowly reducing the dose for an additional 6 months.

NCT Number	NCT07110246
Lead Sponsor	University of California, San Francisco Collaborators: Rising Tide Foundation
Conditions	BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain, Recurrent Low Grade Glioma
Enrollment	96 participants
Start Date	2025-11-07
Primary Completion	2032-03-31 (estimated)
Study Completion	2032-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-03